Collegium Pharma (COLL) reported Q4 EPS of $1.09, in-line with the analyst estimate of $1.09. Revenue for the quarter came in at $129.6 million versus the consensus estimate of $125.2 million.
GUIDANCE:
Collegium Pharma sees FY2023 revenue of $565-580 million, versus the consensus of $569.7 million.